Therapy timing, patient factors, and emerging combination interventions are guiding treatment decisions in multiple myeloma and lymphoma.

The FDA cleared the investigational new drug application for LTZ-301, a first-in-class myeloid engager immunotherapy, with a ...

Jane Fonda is an incredibly strong woman who has been open and candid about her health over the years. The actress and ...

Gwen Nichols, MD, discussed the potential implications of recent funding cuts, how they are affecting academic and community ...

Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative ...

Odronextamab demonstrated a manageable safety profile and generated durable responses in patients with R/R DLBCL who have ...

The four-part docuseries, based on a popular podcast by the same name, follows the story of Amanda Riley, who announced that she had been diagnosed with stage three Hodgkin’s lymphoma in 2012. But not ...

Get real-time breaking news updates on the biggest event unfolding in the United States, including election, politics, ...

The University at Albany women’s lacrosse program hosted its first Tucker Out Lymphoma Game Sunday afternoon at Casey Stadium ...

The University at Albany Great Danes (0-3) women’s lacrosse program will host former America East Rivals No.14 Stony Brook (2 ...

Jack was set for another state championship during his senior year, but in September 2024, he was diagnosed with Hodgkin ...

Some forms of blood cancer, such as multiple myeloma and lymphoma, are malignant diseases that originate from immune cells, specifically lymphocytes.